

REPORTING CHANGES FOR CARBAPENEM RESISTANCE

Effective Date: August 2, 2018

Effective August 2, 2018, antibiotic susceptibility/resistance to the carbapenem class of antibiotics will be reported using interpretations from the Clinical Laboratory Standards Institute (CLSI). Previously, they were interpreted using guidelines from the Food and Drug Administration (FDA). This change has been made in accordance with a recently released FDA update. All carbapenem resistant isolates will be forwarded to the Michigan Department of Health and Human Services for additional testing to determine the molecular basis for this type of resistance. It should be noted that with the change to CLSI interpretations, breakpoints will be one dilution lower, resulting in the reporting of higher numbers of patients with carbapenem resistant organisms.

Turn-around-times will not change for antimicrobial susceptibility testing.

If you have questions, please contact Client Services (1-800-551-0488, option 5).

Laboratory Test Directory: <http://beaumontlaboratory.com/test-lab-directory>.

Date submitted: July 30, 2018

Submitted by: Bobby Boyanton, M.D., Medical Director, Microbiology and Molecular Pathology, Royal Oak

Barbara Robinson-Dunn, Ph.D., D(ABMM), F(AAM), Technical Director, Microbiology, Royal Oak

Beaumont Laboratory
Customer Service
1-800-551-0488

28050 Grand River Ave.
Farmington Hills, MI 48336

468 Cadieux Road
Grosse Pointe, MI 48230

3601 West 13 Mile Road
Royal Oak, MI 48073

44201 Dequindre Road
Troy, MI 48085

www.beaumontlaboratory.com